C Simonelli

Summary

Affiliation: Centro di Riferimento Oncologico
Country: Italy

Publications

  1. ncbi Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma
    Cecilia Simonelli
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    Clin Infect Dis 37:820-7. 2003
  2. ncbi Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma
    Emanuela Vaccher
    Division of Medical Oncology A, Aviano Cancer Institute, Aviano, PN, Italy
    AIDS 19:1915-6. 2005
  3. ncbi Prognostic factors in human herpesvirus 8-related lymphoproliferative disorders associated with HIV infection
    Cecilia Simonelli
    J Clin Oncol 24:209; author reply 209-10. 2006
  4. doi Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection
    C Simonelli
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    J Med Virol 81:888-96. 2009
  5. ncbi Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy
    Cecilia Simonelli
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    Clin Infect Dis 40:1022-7. 2005
  6. pmc Recent thymic emigrants in lymphoma patients with and without human immunodeficiency virus infection candidates for autologous peripheral stem cell transplantation
    C Pratesi
    Microbiology, Immunology and Virology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
    Clin Exp Immunol 151:101-9. 2008
  7. ncbi Presurgical chemotherapy (CT) with FOLFOX4-regimen for patients (pts) with unresectable liver metastases (LM) from colorectal cancer (CRC)
    U Tirelli
    National Cancer Institute, Aviano, Italy University General Hospital, Modena, Italy University of Catania, Catania, Italy
    J Clin Oncol 26:15052. 2008
  8. ncbi The impact of HCV co-infection on the outcome and the clinical features of HIV-related non-Hodgkin lymphoma (NHL)
    C Simonelli
    National Cancer Institute, Aviano, Italy
    J Clin Oncol 26:19504. 2008
  9. ncbi Use of targeted agents in elderly cancer patients (ECP) according to the Comprehensive Geriatric Assessment (CGA)
    L Fratino
    National Cancer Institute, Aviano, Italy
    J Clin Oncol 26:20619. 2008
  10. ncbi MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients
    A Bearz
    Division of Medical Oncology A, National Cancer Institute, Aviano, Pordenone, Italy
    Int J Biol Markers 22:307-11. 2007

Collaborators

Detail Information

Publications27

  1. ncbi Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma
    Cecilia Simonelli
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    Clin Infect Dis 37:820-7. 2003
    ..Our data show that combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of patients receiving this treatment...
  2. ncbi Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma
    Emanuela Vaccher
    Division of Medical Oncology A, Aviano Cancer Institute, Aviano, PN, Italy
    AIDS 19:1915-6. 2005
    ..Irinotecan was well tolerated, severe leukopenia occurred in only 33% of patients. In HIV-infected patients with advanced KS, irinotecan is active and well tolerated...
  3. ncbi Prognostic factors in human herpesvirus 8-related lymphoproliferative disorders associated with HIV infection
    Cecilia Simonelli
    J Clin Oncol 24:209; author reply 209-10. 2006
  4. doi Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection
    C Simonelli
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    J Med Virol 81:888-96. 2009
    ..Multivariate analysis confirmed the diagnosis of lymphoma as an independent predictor of shorter survival...
  5. ncbi Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy
    Cecilia Simonelli
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    Clin Infect Dis 40:1022-7. 2005
    ..The aim of the present study was to evaluate the immunologic and virological parameters, including HHV-8 viremia, of 5 HIV-infected patients with PEL whose disease was diagnosed and treated at our institute...
  6. pmc Recent thymic emigrants in lymphoma patients with and without human immunodeficiency virus infection candidates for autologous peripheral stem cell transplantation
    C Pratesi
    Microbiology, Immunology and Virology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
    Clin Exp Immunol 151:101-9. 2008
    ..Our results suggested that de novo T cell generation is maintained partially in pretreated recurrent lymphoma patients, candidates for ASCT, and could contribute to restore the immune function after transplantation...
  7. ncbi Presurgical chemotherapy (CT) with FOLFOX4-regimen for patients (pts) with unresectable liver metastases (LM) from colorectal cancer (CRC)
    U Tirelli
    National Cancer Institute, Aviano, Italy University General Hospital, Modena, Italy University of Catania, Catania, Italy
    J Clin Oncol 26:15052. 2008
    ..Primary objective of this study was to evaluate resecability rate of LM in pts with un-resectable disease, after "neoadjuvant" CT with FOLFOX4-regimen and secondary objective is to evaluate the objective response and CT toxicity...
  8. ncbi The impact of HCV co-infection on the outcome and the clinical features of HIV-related non-Hodgkin lymphoma (NHL)
    C Simonelli
    National Cancer Institute, Aviano, Italy
    J Clin Oncol 26:19504. 2008
    ..19504 Background: Epidemiological studies show an association between HCV and B NHL. Treatment and outcome of patients with NHL and HCV infection in the general population and in HIV-infected population are still debated...
  9. ncbi Use of targeted agents in elderly cancer patients (ECP) according to the Comprehensive Geriatric Assessment (CGA)
    L Fratino
    National Cancer Institute, Aviano, Italy
    J Clin Oncol 26:20619. 2008
    ..In this study, we describe the results obtained using oral targeted therapies in ECP assessed through the CGA...
  10. ncbi MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients
    A Bearz
    Division of Medical Oncology A, National Cancer Institute, Aviano, Pordenone, Italy
    Int J Biol Markers 22:307-11. 2007
    ..No tumor marker has been validated in the diagnosis and follow-up of lung cancer, in particular to predict the outcome of treatment with EGFR inhibitors...
  11. ncbi FOLFOX4 and concomitant highly active antiretroviral therapy (HAART) in metastatic colorectal cancer (M-CRC) HIV-positive patients (pts): A GICAT experience
    M Berretta
    National Cancer Institute, Aviano, Italy University of Verona, Verona, Italy Cotugno Hospital, Napoli, Italy General Hospital, Rimini, Italy General Hospital, Livorno, Italy University General Hospital, Modena, Italy
    J Clin Oncol 26:15046. 2008
    ..15046 Background: This study was performed to evaluate retrospectively the efficacy and tolerance of FOLFOX4 regimen, with concomitant HAART, in M-CRC HIV-positive pts...
  12. ncbi Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report
    M Berretta
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    J Chemother 19:343-6. 2007
    ..This case suggests that, in the HAART era, a multidisciplinary approach can be offered to HIV patients with advanced cancer when they have good performance status, resulting in efficacious control of the HIV infection...
  13. ncbi Pemetrexed in second-line treatment in advanced NSCLC: An experience on 131 patients
    A Bearz
    National Cancer Institute, Aviano, Italy IRCCS Humanitas, Milano, Italy Veneto Oncologic Institute, Padova, Italy General Hospital, Pordenone, Italy
    J Clin Oncol 26:19114. 2008
    ..Herein we analyzed the data about patients in second-line therapy only, 128, which we added data from 3 more patients...
  14. ncbi Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial
    D Bernardi
    Division of Medical Oncology A, Centro di Riferimento Oncologico, Aviano PN, Italy
    Prostate Cancer Prostatic Dis 7:45-9. 2004
    ....
  15. ncbi Unusual presentation of metastatic hepatocellular carcinoma in an HIV/HCV coinfected patient: case report and review of the literature
    Massimiliano Berretta
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    Tumori 94:589-91. 2008
    ..The case series of HCC in HIV-positive individuals published to date does not cumulatively exceed 70 subjects...
  16. doi Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer
    Massimiliano Berretta
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    Onkologie 31:394-7. 2008
    ..To date, there is little evidence in the English literature about chemotherapy treatment in HIV-positive patients with metastatic colorectal cancer...
  17. doi FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature
    Massimiliano Berretta
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    Cancer Invest 26:610-4. 2008
    ..Moreover, the concomitant use of HAART does not seem to increase the toxicity of the FOLFOX-4 regimen...
  18. ncbi Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study
    Alessandra Bearz
    Medical Oncology A, IRCCS CRO, Via Franco Gallini 2, 33081 Aviano, Italy
    Lung Cancer 60:240-5. 2008
    ..We evaluated the activity and toxicity of Pemetrexed, in a post-registration phase, to assess whether clinical benefits justify its employment in a second-line setting in routine clinical practice...
  19. ncbi Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma
    Michele Spina
    J Clin Oncol 25:e7. 2007
  20. ncbi Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy
    Emanuela Vaccher
    Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
    Clin Infect Dis 37:1556-64. 2003
    ..42-40.25), 9.11 (95% CI, 3.71-22.32), and 8.54 (95% CI, 1.19-61.11), respectively. Our study suggests that the long-term use of HAART may favorably change the outcome for patients with systemic HIV-NHL...
  21. ncbi Virological efficacy in HIV-infected patients affected by non-Hodgkin lymphoma, treated with antiblastic chemotherapy and highly active antiretroviral therapy
    Cecilia Simonelli
    Divisione di Oncologia Medica A, Istituto Nazionale Tumori, Aviano, Italy
    Scand J Infect Dis Suppl 106:49-53. 2003
    ..The data show that a combination therapy consisting of CT and HAART is feasible and that the virological response can be maintained in the majority of such patients...
  22. ncbi Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era
    Michele Spina
    J Clin Oncol 23:8132-3; author reply 8133-4. 2005
  23. ncbi Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials
    Michele Spina
    Division of Medical Oncology A, National Cancer Institute, Via Pedemontana Occidentale 12, 33081, Aviano PN Italy
    Blood 105:1891-7. 2005
    ..Further studies evaluating rituximab in combination with infusional chemotherapy are warranted, but caution is advised...
  24. ncbi Hepatitis C virus infection does not prevent autologous bone marrow transplantation in HIV-related non-Hodgkin's lymphoma
    Cecilia Simonelli
    AIDS 18:1859-61. 2004
  25. ncbi Effects on virological and immunological parameters during CD34 mobilization in HIV patients with lymphoma
    Maria Teresa Bortolin
    Microbiology, Immunology and Virology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
    Am J Hematol 81:800-2. 2006
    ..After mobilization, CD4+ cells increased significantly while HIV-RNA and integrated HIV-DNA showed no increases. G-CSF led to an increase of CD4+ cells with limited effects on HIV replication...
  26. ncbi Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)
    Alessandra Bearz
    Lung Cancer 55:125-7. 2007
  27. ncbi Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development
    Maria Caterina Sirianni
    Clinical Immunology, Department of Clinical Medicine, University of Roma La Sapienza, Italy
    Br J Haematol 130:92-5. 2005
    ..Intriguingly, analysis of MHC-I non-restricted cytotoxicity in two PEL patients indicated a reduced NK cell activity when compared with healthy individuals. These data suggest that PEL outgrowth may require an impaired NK cell function...